Oncologic Drug QoL Data Useful After Treatment Failure - FDA Cmte.
Executive Summary
Quality of life assessments should be collected even after treatment failure, a subcommittee of FDA's Oncologic Drugs Advisory Committee suggested at a Feb. 10 meeting in Bethesda, Md.